WO2010027010A1 - 有効成分が境界を有してなる医薬固形製剤 - Google Patents
有効成分が境界を有してなる医薬固形製剤 Download PDFInfo
- Publication number
- WO2010027010A1 WO2010027010A1 PCT/JP2009/065390 JP2009065390W WO2010027010A1 WO 2010027010 A1 WO2010027010 A1 WO 2010027010A1 JP 2009065390 W JP2009065390 W JP 2009065390W WO 2010027010 A1 WO2010027010 A1 WO 2010027010A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- granules
- acid
- solid preparation
- mixed
- cysteine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Definitions
- the present invention relates to a solid preparation for internal use in which tranexamic acid and ascorbic acid are present via a boundary, and are unlikely to cause discoloration of the preparation.
- Tranexamic acid has anti-bleeding, anti-allergy, anti-inflammatory effects, etc. as an antiplasmin agent, is widely used as a medical drug, and is also included in OTC drugs.
- tranexamic acid has been prescribed for the treatment of melasma after it was reported that the occasional concurrent melasma had disappeared (For example, see Non-Patent Document 1).
- Ascorbic acid has long been known to suppress pigmentation by suppressing the production of melanin pigments and degrading the accumulated melanin pigments, and OTC drugs are approved as vitamin C main drug formulations.
- OTC drugs are approved as vitamin C main drug formulations.
- pigmentation due to stains, freckles, sunburn and rashes has been observed (see Non-Patent Document 2).
- Patent Document 1 a pigmentation treatment preparation containing tranexamic acid and ascorbic acid has been disclosed, and it has been reported that the improvement degree of pigmentation is superior to the case where tranexamic acid alone or ascorbic acid alone is administered.
- a whitening composition containing tranexamic acid, ascorbic acid and L-cysteine has been disclosed by the present inventors, and it has been found that pigmentation is further suppressed than the combined use of tranexamic acid and ascorbic acid (patent) Reference 2).
- an object of the present invention is to provide a solid preparation for internal use which has no discoloration and has excellent stability in a preparation containing tranexamic acid and ascorbic acid.
- Discoloration of the preparation can be suppressed by producing the preparation separately from (a) granules containing tranexamic acid and (b) granules containing ascorbic acid. 2. Furthermore, In the case where ⁇ pyridoxine '' is contained in the preparation described in Discoloration of the preparation can be suppressed by incorporating L-cysteine in the granule containing pyridoxine. 3. Furthermore, In the case where “L-cysteine” is contained in the preparation described in 1.
- pantothenic acid By including pantothenic acid in the granule containing L-cysteine, discoloration of the preparation can be suppressed. 4). Furthermore, When adding ⁇ pyridoxine and pantothenic acid '' to the preparation described in By incorporating L-cysteine in the granule containing pyridoxine and pantothenic acid, discoloration of the preparation can be suppressed.
- a solid preparation for internal use comprising tranexamic acid and ascorbic acid as active ingredients, which are present via a boundary in the preparation.
- a solid preparation for internal use wherein (a) a component comprising tranexamic acid as an active ingredient and (b) a component comprising ascorbic acid as an active ingredient are contained via a boundary.
- the solid preparation according to (2) wherein the component according to (2) is a granule.
- the present invention is useful because it is a stable solid preparation for internal use in which preparation discoloration is suppressed even when tranexamic acid and ascorbic acid are blended. Further, even when L-cysteine, pyridoxine or / and pantothenic acid is contained, it is useful because it is a solid preparation for stable internal use in which discoloration of the preparation is suppressed.
- the “pyridoxine” of the present invention is pyridoxine and a salt thereof, and is preferably pyridoxine hydrochloride.
- pantothenic acid of the present invention is pantothenic acid and its salt, preferably calcium pantothenate.
- the “solid preparation” of the present invention refers to granules, pills, powders, tablets, capsules and the like described in the 15th revision Japanese Pharmacopoeia.
- the solid preparation for internal use of the present invention is preferably a granule, powder, capsule or tablet.
- a suitable aspect of the granule or tablet of this invention what gave the sugar coating or what performed the film coating is mentioned. That is, sugar-coated granules, film-coated granules, sugar-coated tablets, film-coated tablets and the like can be mentioned.
- the solid preparation for internal use of the present invention is a tablet
- a multilayer tablet obtained by compressing and molding powders or granules having different compositions in two layers or three or more layers is also mentioned as a preferred embodiment.
- “exists through a boundary” means that when a plurality of drugs are present in a solid preparation, the drugs directly react with each other without the drugs being uniformly mixed. It refers to a state existing in the same solid preparation.
- a method for producing the solid preparation of the present invention for example, (1) (a) Granules containing tranexamic acid and (b) granules containing ascorbic acid are individually produced. (2) In the case of tablets, a step of compression molding after mixing the granules. Can be mentioned.
- the content ratio is ascorbic acid and L-cysteine, respectively, per 1 part by weight of tranexamic acid.
- the content ratio of pyridoxine hydrochloride and calcium pantothenate is as follows. Preferred are 0.01 to 10 parts by weight, 0.01 to 10 parts by weight, 0.001 to 1 part by weight, and 0.001 to 1 part by weight, and more preferably 0.1 to 2 parts by weight. 0.1 to 2 parts by weight, 0.001 to 0.5 parts by weight and 0.01 to 0.5 parts by weight.
- Talc was mixed with the granules and a part was used as test granules. The remaining granules were mixed with crystalline cellulose, croscarmellose sodium and magnesium stearate and then tableted to obtain tablets.
- Comparative Example 2 In a fluidized bed granulator, 96.2 g of tranexamic acid, 38.5 g of ascorbic acid, 30.8 g of L-cysteine, 0.8 g of pyridoxine hydrochloride, and appropriate amounts of crystalline cellulose are added and mixed, and an aqueous hydroxypropylcellulose solution is sprayed and granulated. Got.
- Talc was mixed with the granules and a part was used as test granules. The remaining granules were mixed with crystalline cellulose, croscarmellose sodium and magnesium stearate and then tableted to obtain tablets.
- Comparative Example 3 In a fluidized bed granulator, 750 mg of tranexamic acid, 300 mg of ascorbic acid, 240 mg of L-cysteine, 37 mg of calcium pantothenate, 6 mg of pyridoxine hydrochloride and appropriate amounts of crystalline cellulose were added and mixed, and an aqueous hydroxypropylcellulose solution was sprayed to obtain granules.
- Talc was mixed with the granules and a part was used as test granules. The remaining granules were mixed with crystalline cellulose, croscarmellose sodium and magnesium stearate and then tableted to obtain tablets.
- Comparative Example 4 In a fluidized bed granulator, 96.2 g of tranexamic acid, 38.5 g of ascorbic acid, and appropriate amounts of crystalline cellulose were added and mixed, and an aqueous hydroxypropylcellulose solution was sprayed to obtain granules 1.
- Talc was mixed with the granules and a part was used as test granules. The remaining granules were mixed with crystalline cellulose, croscarmellose sodium and magnesium stearate and then tableted to obtain tablets.
- Comparative Example 5 In a fluidized bed granulator, 96.2 g of tranexamic acid, 30.8 g of L-cysteine, and appropriate amounts of crystalline cellulose were added and mixed, and an aqueous hydroxypropylcellulose solution was sprayed to form granules a.
- Talc was mixed with the granules and a part was used as test granules. The remaining granules were mixed with crystalline cellulose, croscarmellose sodium and magnesium stearate and then tableted to obtain tablets.
- Comparative Example 6 In a fluidized bed granulator, 96.2 g of tranexamic acid, 0.8 g of pyridoxine hydrochloride and an appropriate amount of crystalline cellulose were added and mixed, and an aqueous hydroxypropylcellulose solution was sprayed to obtain granules a.
- Talc was mixed with the granules and a part was used as test granules. The remaining granules were mixed with crystalline cellulose, croscarmellose sodium and magnesium stearate and then tableted to obtain tablets.
- Comparative Example 7 A fluidized bed granulator was charged with 96.2 g of tranexamic acid, 4.7 g of calcium pantothenate, 0.8 g of pyridoxine hydrochloride and an appropriate amount of crystalline cellulose, and sprayed with an aqueous hydroxypropylcellulose solution to obtain granules a.
- Talc was mixed with the granules and a part was used as test granules. The remaining granules were mixed with crystalline cellulose, croscarmellose sodium and magnesium stearate and then tableted to obtain tablets.
- Comparative Example 8 A fluidized bed granulator was charged with 96.2 g of tranexamic acid, 30.8 g of L-cysteine, 4.7 g of calcium pantothenate, and appropriate amounts of crystalline cellulose, and sprayed with an aqueous hydroxypropylcellulose solution to obtain granules a.
- Talc was mixed with the granules and a part was used as test granules. The remaining granules were mixed with crystalline cellulose, croscarmellose sodium and magnesium stearate and then tableted to obtain tablets.
- Example 1 In a fluidized bed granulator, 96.2 g of tranexamic acid and an appropriate amount of crystalline cellulose were added and mixed, and an aqueous hydroxypropylcellulose solution was sprayed to obtain granules a. Further, 38.5 g of ascorbic acid and an appropriate amount of crystalline cellulose were added and mixed, and an aqueous hydroxypropylcellulose solution was sprayed to obtain granules b.
- Example 2 Talc was mixed with the granules and a part was used as test granules. The remaining granules were mixed with crystalline cellulose, croscarmellose sodium and magnesium stearate and then tableted to obtain tablets. (Example 2) In a fluidized bed granulator, 96.2 g of tranexamic acid and an appropriate amount of crystalline cellulose were added and mixed, and an aqueous hydroxypropylcellulose solution was sprayed to obtain granules a.
- Example 4 In a fluidized bed granulator, 2403.8 g of tranexamic acid, 769.2 g of L-cysteine, 118.6 g of calcium pantothenate, 19.2 g of pyridoxine hydrochloride, and appropriate amounts of crystalline cellulose are mixed and sprayed with an aqueous hydroxypropylcellulose granule. a. Further, 961.5 g of ascorbic acid and an appropriate amount of crystalline cellulose were added and mixed, and an aqueous hydroxypropylcellulose solution was sprayed to obtain granules b.
- Talc was mixed with the granules and a part was used as test granules. The remaining granules were mixed with crystalline cellulose, croscarmellose sodium and magnesium stearate and then tableted to obtain tablets. (Example 5) In a fluidized bed granulator, 2403.8 g of tranexamic acid, 118.6 g of calcium pantothenate, and appropriate amounts of crystalline cellulose were added and mixed, and an aqueous hydroxypropylcellulose solution was sprayed to obtain granules a.
- discoloration can be remarkably suppressed by adding L-cysteine together with pyridoxine in both (a) tranexamic acid-containing granules and (b) ascorbic acid-containing granules. From the results shown in Table 4, when tranexamic acid and ascorbic acid are separated via a boundary, and when L-cysteine is further contained, discoloration can occur. Even in such a case, discoloration can be remarkably suppressed by adding (a) tranexamic acid-containing granules to pantothenic acid together with L-cysteine, or (b) ascorbic acid-containing granules containing L-cysteine.
- pyridoxine hydrochloride represents pyridoxine hydrochloride
- pantothenic acid Ca represents calcium pantothenate
- pyridoxine hydrochloride indicates pyridoxine hydrochloride
- pantothenic acid Ca indicates calcium pantothenate
- pyridoxine hydrochloride represents pyridoxine hydrochloride
- pantothenic acid Ca represents calcium pantothenate.
- pyridoxine hydrochloride represents pyridoxine hydrochloride
- pantothenic acid Ca represents calcium pantothenate
Abstract
Description
1.(a)トラネキサム酸を含有する顆粒と、(b)アスコルビン酸を含有する顆粒とに分けて製剤を製造することにより製剤変色を抑制することができる。
2.更に、1.に記載の製剤に、「ピリドキシン」を含有させる場合には、
ピリドキシンを含有する顆粒中に、L-システインを含有させることにより、製剤変色を抑制することができる。
3.更に、1.に記載の製剤に、「L-システイン」を含有させる場合には、
L-システインを含有する顆粒中に、パントテン酸を含有させることにより、製剤変色を抑制することができる。
4.更に、1.に記載の製剤に、「ピリドキシン及びパントテン酸」を配合させる場合には、
ピリドキシン及びパントテン酸を含有する顆粒中に、L-システインを含有させることにより、製剤変色を抑制することができる。
(1)
有効成分としてトラネキサム酸及びアスコルビン酸からなり、それらが製剤中に境界を介して存在してなることを特徴とする内服用の固形製剤。
(2)
(a)有効成分としてトラネキサム酸からなる成分と、(b)有効成分としてアスコルビン酸からなる成分と、が境界を介して含有することを特徴とする内服用の固形製剤。
(3)
(2)に記載の成分が顆粒である、(2)に記載の固形製剤。
(4)
(a)、(b)のどちらか一方、又は、双方に、L-システイン及びピリドキシンを含有する(2)又は(3)に記載の固形製剤。
(5)
(a)、(b)のどちらか一方、又は、双方に、L-システイン及びパントテン酸を含有する(2)又は(3)に記載の固形製剤。
(6)
(a)、(b)のどちらか一方、又は、双方に、L-システイン、パントテン酸及びピリドキシンを含有する(2)又は(3)に記載の固形製剤。
(7)
ピリドキシンがピリドキシン塩酸塩である(4)又は(6)に記載の内服用の固形製剤。
(8)
パントテン酸がパントテン酸カルシウムである(5)又は(6)に記載の内服用の固形製剤。
本発明の内服用の固形製剤として、好適には、顆粒剤、散剤、カプセル剤又は錠剤である。
また、本発明の顆粒剤又は錠剤の好適な態様として、糖衣を施したもの又はフィルムコーティングを行ったものが挙げられる。すなわち、糖衣顆粒、フィルムコーティング顆粒、糖衣錠、フィルムコーティング錠等が挙げられる。
本発明の内服用の固形製剤が錠剤の場合、組成の異なる粉末又は顆粒を2層または3層以上に積み重ねて圧縮成型した多層錠も好ましい態様として挙げられる。
本発明の「互いに境界を介して存在する」とは、固形製剤中に複数の薬剤等が存在する場合に、それらの薬剤等が均一に混合して存在することなく、直接薬剤同士が反応することがなく、同一の固形製剤中に存在する状態をいう。例えば、それぞれの薬剤の間に結合剤や賦形剤等の薬剤と反応しない物質が存在したり、それぞれの薬剤が異なる顆粒中に存在する複数の顆粒として存在したりする固形製剤が挙げられる。
(1)(a)トラネキサム酸を含有する顆粒と、(b)アスコルビン酸を含有する顆粒とをそれぞれ個別に製造する
(2)錠剤の場合は、各顆粒を混合した後、圧縮成型する
という工程を経る方法を挙げることができる。
また、L-システインは、医薬品添加物規格2003に収載されている。
好適には、0.01~10重量部、0.01~10重量部、0.001~1重量部及び0.001~1重量部であり、より好適には、0.1~2重量部、0.1~2重量部、0.001~0.5重量部及び0.01~0.5重量部である。
1.試験用顆粒及び錠剤の製造
(比較例1)
流動層造粒機にトラネキサム酸96.2g、アスコルビン酸38.5g、結晶セルロース適量を投入・混合し、ヒドロキシプロピルセルロース水溶液を噴霧し顆粒剤を得た。
(比較例2)
流動層造粒機にトラネキサム酸96.2g、アスコルビン酸38.5g、L-システイン30.8g、ピリドキシン塩酸塩0.8g、結晶セルロース適量を投入・混合し、ヒドロキシプロピルセルロース水溶液を噴霧し顆粒剤を得た。
(比較例3)
流動層造粒機にトラネキサム酸750mg、アスコルビン酸300mg、L-システイン240mg、パントテン酸カルシウム37mg、ピリドキシン塩酸塩6mgおよび結晶セルロース適量を投入・混合し、ヒドロキシプロピルセルロース水溶液を噴霧し顆粒を得た。
(比較例4)
流動層造粒機にトラネキサム酸96.2g、アスコルビン酸38.5g、結晶セルロース適量を投入・混合し、ヒドロキシプロピルセルロース水溶液を噴霧し顆粒1を得た。また、L-システイン30.8g、パントテン酸カルシウム4.7g、ピリドキシン塩酸塩0.8g、結晶セルロース適量を投入・混合し、ヒドロキシプロピルセルロース水溶液を噴霧し顆粒2を得た。
(比較例5)
流動層造粒機にトラネキサム酸96.2g、L-システイン30.8g、結晶セルロース適量を投入・混合し、ヒドロキシプロピルセルロース水溶液を噴霧し顆粒aとした。また、アスコルビン酸38.5g、パントテン酸カルシウム4.7g、ピリドキシン塩酸塩0.8g、結晶セルロース適量を投入・混合し、ヒドロキシプロピルセルロース水溶液を噴霧し顆粒bを得た。
(比較例6)
流動層造粒機にトラネキサム酸96.2g、ピリドキシン塩酸塩0.8g、結晶セルロース適量を投入・混合し、ヒドロキシプロピルセルロース水溶液を噴霧し顆粒aを得た。また、アスコルビン酸38.5g、L-システイン30.8g、パントテン酸カルシウム4.7g、結晶セルロース適量を投入・混合し、ヒドロキシプロピルセルロース水溶液を噴霧し顆粒bを得た。
(比較例7)
流動層造粒機にトラネキサム酸96.2g、パントテン酸カルシウム4.7g、ピリドキシン塩酸塩0.8g、結晶セルロース適量を投入・混合し、ヒドロキシプロピルセルロース水溶液を噴霧し顆粒aを得た。また、L-システイン30.8g、アスコルビン酸38.5g、結晶セルロース適量を投入・混合し、ヒドロキシプロピルセルロース水溶液を噴霧し顆粒bを得た。
(比較例8)
流動層造粒機にトラネキサム酸96.2g、L-システイン30.8g、パントテン酸カルシウム4.7g、結晶セルロース適量を投入・混合し、ヒドロキシプロピルセルロース水溶液を噴霧し顆粒aを得た。また、アスコルビン酸38.5g、ピリドキシン塩酸塩0.8g、結晶セルロース適量を投入・混合し、ヒドロキシプロピルセルロース水溶液を噴霧し顆粒bを得た。
(実施例1)
流動層造粒機にトラネキサム酸96.2gと結晶セルロース適量を投入・混合し、ヒドロキシプロピルセルロース水溶液を噴霧し顆粒aを得た。また、アスコルビン酸38.5gと結晶セルロース適量を投入・混合し、ヒドロキシプロピルセルロース水溶液を噴霧し顆粒bを得た。
(実施例2)
流動層造粒機にトラネキサム酸96.2gと結晶セルロース適量を投入・混合し、ヒドロキシプロピルセルロース水溶液を噴霧し顆粒aを得た。また、アスコルビン酸38.5g、L-システイン30.8g、ピリドキシン塩酸塩0.8g、結晶セルロース適量を投入・混合し、ヒドロキシプロピルセルロース水溶液を噴霧し顆粒bを得た。
(実施例3)
流動層造粒機にトラネキサム酸96.2gと結晶セルロース適量を投入・混合し、ヒドロキシプロピルセルロース水溶液を噴霧し顆粒aを得た。また、アスコルビン酸38.5g、L-システイン30.8g、パントテン酸カルシウム4.7g、ピリドキシン塩酸塩0.8g、結晶セルロース適量を投入・混合し、ヒドロキシプロピルセルロース水溶液を噴霧し顆粒bを得た。
(実施例4)
流動層造粒機にトラネキサム酸2403.8g、L-システイン769.2g、パントテン酸カルシウム118.6g、ピリドキシン塩酸塩19.2g、結晶セルロース適量を投入・混合し、ヒドロキシプロピルセルロース水溶液を噴霧し顆粒aとした。また、アスコルビン酸961.5g、結晶セルロース適量を投入・混合し、ヒドロキシプロピルセルロース水溶液を噴霧し顆粒bとした。
(実施例5)
流動層造粒機にトラネキサム酸2403.8g、パントテン酸カルシウム118.6g、結晶セルロース適量を投入・混合し、ヒドロキシプロピルセルロース水溶液を噴霧し顆粒aとした。また、アスコルビン酸961.5g、L-システイン769.2g、ピリドキシン塩酸塩19.2g、結晶セルロース適量を投入・混合し、ヒドロキシプロピルセルロース水溶液を噴霧し顆粒bとした。
2.試験方法
実施例1-5及び比較例1-8の顆粒、並びに、当該顆粒を用いて打錠した錠剤につき、50℃で4日放置(比較例3のみ成り行き室温で2週間)し、冷蔵庫保存品を対照として各顆粒および錠剤の変色を目視により観察した。なお、目視での評価は以下の基準を用いた。
(評価の基準)
A:変色なし
B:わずかな変色
C:変色あり
D:著しい変色
3.試験結果
表1の結果より、トラネキサム酸とアスコルビン酸とを境界を介して分離させなかった場合には、製剤に変色が発現することが判った。一方、トラネキサム酸とアスコルビン酸とを境界を介して分離させた場合には、製剤の変色は著しく抑制されることが判明した。
このような場合でも、(a)トラネキサム酸を含有する顆粒に、ピリドキシンとともにL-システインを含有させることにより変色が著しく抑制できること、又は、(b)アスコルビン酸を含有する顆粒に、ピリドキシンとともにL-システインを含有させることにより変色が著しく抑制できること、がわかった。
表4の結果より、トラネキサム酸とアスコルビン酸とを境界を介して分離させた場合に、更に、L-システインを含有させた場合には、変色が生じ得る。
このような場合でも、(a)トラネキサム酸を含有する顆粒に、L-システインとともにパントテン酸を含有させることにより変色が著しく抑制できること、又は、(b)アスコルビン酸を含有する顆粒に、L-システインとともにパントテン酸を含有させることにより変色が著しく抑制できること、がわかった。
表5の結果より、トラネキサム酸とアスコルビン酸とを境界を介して分離させた場合に、更に、ピリドキシンとパントテン酸を同一顆粒中に存在させた場合にも、変色を生じることが判った。
このような場合でも、(a)トラネキサム酸を含有する顆粒に、ピリドキシンとパントテン酸とともにL-システインを含有させることにより変色が著しく抑制できること、又は、(b)アスコルビン酸を含有する顆粒に、ピリドキシンとパントテン酸とともにL-システインを含有させることにより変色が著しく抑制できること、がわかった。
以上、表2-5の結果をまとめると、トラネキサム酸とアスコルビン酸とを境界を介して分離させた場合に、更に、薬剤を含有させた場合の変色を抑制するためには、以下のようにすればよいことがわかった。
(1)更に、ピリドキシンを含有させる場合には、同一成分中に、L-システインとともに含有させること。
(2)更に、L-システインを含有させる場合には、同一成分中に、パントテン酸とともに含有させること。
(3)更に、ピリドキシンとパントテン酸を含有させる場合には、同一成分中に、L-システインを含有させること。
Claims (8)
- 有効成分としてトラネキサム酸及びアスコルビン酸からなり、それらが製剤中に境界を介して存在してなることを特徴とする内服用の固形製剤。
- (a)有効成分としてトラネキサム酸からなる成分と、(b)有効成分としてアスコルビン酸からなる成分と、が境界を介して含有することを特徴とする内服用の固形製剤。
- 請求項2に記載の成分が顆粒である、請求項2に記載の固形製剤。
- (a)、(b)のどちらか一方、又は、双方に、L-システイン及びピリドキシンを含有する請求項2又は3に記載の固形製剤。
- (a)、(b)のどちらか一方、又は、双方に、L-システイン及びパントテン酸を含有する請求項2又は3に記載の固形製剤。
- (a)、(b)のどちらか一方、又は、双方に、L-システイン、パントテン酸及びピリドキシンを含有する請求項2又は3に記載の固形製剤。
- ピリドキシンがピリドキシン塩酸塩である請求項4又は6に記載の内服用の固形製剤。
- パントテン酸がパントテン酸カルシウムである請求項5又は6に記載の内服用の固形製剤。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0919194A BRPI0919194A2 (pt) | 2008-09-05 | 2009-09-03 | preparação sólida para administração oral |
JP2010527810A JP5579066B2 (ja) | 2008-09-05 | 2009-09-03 | 有効成分が境界を有してなる医薬固形製剤 |
MX2011002400A MX2011002400A (es) | 2008-09-05 | 2009-09-03 | Preparacion farmaceutica solida que tiene ingredientes activos separados por limites en la misma. |
CN200980134233.8A CN102137664B (zh) | 2008-09-05 | 2009-09-03 | 具有被边界隔开的有效成分的固体药物制剂 |
EP09811535.5A EP2335698B8 (en) | 2008-09-05 | 2009-09-03 | Pharmaceutical solid preparation having active ingredients separated by boundary therein |
HK11106770.0A HK1152652A1 (en) | 2008-09-05 | 2011-07-04 | Pharmaceutical solid preparation having active ingredients separated by boundary therein |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008-227971 | 2008-09-05 | ||
JP2008227971 | 2008-09-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010027010A1 true WO2010027010A1 (ja) | 2010-03-11 |
Family
ID=41797176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/065390 WO2010027010A1 (ja) | 2008-09-05 | 2009-09-03 | 有効成分が境界を有してなる医薬固形製剤 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2335698B8 (ja) |
JP (1) | JP5579066B2 (ja) |
KR (1) | KR101640958B1 (ja) |
CN (1) | CN102137664B (ja) |
BR (1) | BRPI0919194A2 (ja) |
HK (1) | HK1152652A1 (ja) |
MX (1) | MX2011002400A (ja) |
TW (1) | TWI436763B (ja) |
WO (1) | WO2010027010A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2695605A1 (en) | 2012-08-07 | 2014-02-12 | Disphar International B.V. | Tranexamic acid composition |
JP5498387B2 (ja) * | 2008-09-12 | 2014-05-21 | 第一三共ヘルスケア株式会社 | 変色が抑制された安定な医薬製剤 |
JP2021001126A (ja) * | 2019-06-20 | 2021-01-07 | 小林製薬株式会社 | ケラチノサイト内メラノソーム分解促進剤 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103054861A (zh) * | 2012-12-29 | 2013-04-24 | 北京阜康仁生物制药科技有限公司 | 一种含氨甲环酸的复方固体制剂 |
CN109793757B (zh) * | 2019-03-28 | 2021-06-22 | 北京刷新活力健康科技有限公司 | 一种抑制皮肤瘢痕生长的组合物及其制备方法和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04243825A (ja) | 1991-01-25 | 1992-08-31 | Ss Pharmaceut Co Ltd | 色素沈着症治療剤 |
JP2004091473A (ja) * | 2002-07-12 | 2004-03-25 | Tadayasu Takada | 色素沈着改善治療薬 |
JP2004217655A (ja) | 2002-12-27 | 2004-08-05 | Dai Ichi Seiyaku Co Ltd | 美白用組成物 |
WO2006003965A1 (ja) * | 2004-06-30 | 2006-01-12 | Daiichi Sankyo Healthcare Co., Ltd. | 美白組成物 |
JP2007131547A (ja) * | 2005-11-08 | 2007-05-31 | Shiseido Co Ltd | イオントフォレーシスによる美容方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01102073A (ja) * | 1987-10-15 | 1989-04-19 | Takeda Chem Ind Ltd | 安定なアスコルビン酸粉末およびその製造法 |
TW271406B (ja) * | 1992-04-17 | 1996-03-01 | Takeda Pharm Industry Co Ltd | |
JP2001294524A (ja) * | 2000-04-12 | 2001-10-23 | Taisho Pharmaceut Co Ltd | アセトアミノフェン配合内服固形製剤 |
KR20080022592A (ko) * | 2002-12-27 | 2008-03-11 | 다이이찌 세이야꾸 가부시기가이샤 | 미백용 조성물 |
US8277844B2 (en) * | 2003-08-20 | 2012-10-02 | Shionogi & Co., Ltd. | Coating composition |
JP2005314403A (ja) * | 2004-03-31 | 2005-11-10 | Dai Ichi Seiyaku Co Ltd | 新規美白用組成物 |
JP2008201711A (ja) * | 2007-02-20 | 2008-09-04 | Ss Pharmaceut Co Ltd | システイン臭が低減された固形製剤 |
-
2009
- 2009-09-03 JP JP2010527810A patent/JP5579066B2/ja active Active
- 2009-09-03 WO PCT/JP2009/065390 patent/WO2010027010A1/ja active Application Filing
- 2009-09-03 EP EP09811535.5A patent/EP2335698B8/en active Active
- 2009-09-03 MX MX2011002400A patent/MX2011002400A/es not_active Application Discontinuation
- 2009-09-03 KR KR1020117005172A patent/KR101640958B1/ko active IP Right Grant
- 2009-09-03 BR BRPI0919194A patent/BRPI0919194A2/pt not_active IP Right Cessation
- 2009-09-03 CN CN200980134233.8A patent/CN102137664B/zh active Active
- 2009-09-04 TW TW098129783A patent/TWI436763B/zh active
-
2011
- 2011-07-04 HK HK11106770.0A patent/HK1152652A1/xx unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04243825A (ja) | 1991-01-25 | 1992-08-31 | Ss Pharmaceut Co Ltd | 色素沈着症治療剤 |
JP2004091473A (ja) * | 2002-07-12 | 2004-03-25 | Tadayasu Takada | 色素沈着改善治療薬 |
JP2004217655A (ja) | 2002-12-27 | 2004-08-05 | Dai Ichi Seiyaku Co Ltd | 美白用組成物 |
WO2006003965A1 (ja) * | 2004-06-30 | 2006-01-12 | Daiichi Sankyo Healthcare Co., Ltd. | 美白組成物 |
JP2007131547A (ja) * | 2005-11-08 | 2007-05-31 | Shiseido Co Ltd | イオントフォレーシスによる美容方法 |
Non-Patent Citations (5)
Title |
---|
"Approval Standards for Manufacturing (Import) of Non-Prescription Drugs", IPPAN-YO IYAKUHIN SEIZO, 2008 |
"Japanese Pharmacopoeia" |
JAPANESE PHARMACEUTICAL EXCIPIENTS, 2003 |
PHARMACIA, vol. 44, no. 5, 2008, pages 437 - 442 |
See also references of EP2335698A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5498387B2 (ja) * | 2008-09-12 | 2014-05-21 | 第一三共ヘルスケア株式会社 | 変色が抑制された安定な医薬製剤 |
EP2695605A1 (en) | 2012-08-07 | 2014-02-12 | Disphar International B.V. | Tranexamic acid composition |
JP2021001126A (ja) * | 2019-06-20 | 2021-01-07 | 小林製薬株式会社 | ケラチノサイト内メラノソーム分解促進剤 |
Also Published As
Publication number | Publication date |
---|---|
HK1152652A1 (en) | 2012-03-09 |
CN102137664A (zh) | 2011-07-27 |
JP5579066B2 (ja) | 2014-08-27 |
TW201016213A (en) | 2010-05-01 |
EP2335698B8 (en) | 2014-06-25 |
BRPI0919194A2 (pt) | 2015-12-15 |
JPWO2010027010A1 (ja) | 2012-02-02 |
EP2335698A4 (en) | 2011-10-12 |
KR20110057145A (ko) | 2011-05-31 |
CN102137664B (zh) | 2014-08-06 |
MX2011002400A (es) | 2011-04-07 |
EP2335698A1 (en) | 2011-06-22 |
TWI436763B (zh) | 2014-05-11 |
KR101640958B1 (ko) | 2016-07-19 |
EP2335698B1 (en) | 2014-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5517938B2 (ja) | 安定なトラネキサム酸とアスコルビン酸含有医薬組成物 | |
JP2010518822A5 (ja) | ||
JP5498387B2 (ja) | 変色が抑制された安定な医薬製剤 | |
KR20170128323A (ko) | 착색제를 함유하는 고형 제제 | |
JP5579066B2 (ja) | 有効成分が境界を有してなる医薬固形製剤 | |
JP2016104812A (ja) | ロキソプロフェンナトリウム及びトラネキサム酸を含有する固形製剤 | |
JP5694177B2 (ja) | 変色及び臭いが抑制されたフィルムコーティング錠 | |
KR20170128319A (ko) | 항산화제를 함유하는 고형 제제 | |
JP2014118380A (ja) | ベンズイミダゾール−7−カルボン酸誘導体含有錠剤組成物 | |
JP2016050206A (ja) | レボカルニチンを含有する医薬錠剤 | |
JP6114573B2 (ja) | ロキソプロフェンナトリウムと制酸剤を含有する固形製剤 | |
JP6106359B2 (ja) | ロキソプロフェンナトリウムとビタミンb1を含有する固形製剤 | |
JP6439503B2 (ja) | 固形製剤 | |
JP5837847B2 (ja) | セチリジン塩酸塩を含有する医薬組成物 | |
JP6112765B2 (ja) | ロキソプロフェンナトリウム及びdl−メチルエフェドリン塩酸塩を含有する固形製剤 | |
KR20230019034A (ko) | DiMit(Discoloration Minimizing technology) 기술을 이용하여 성상 안정성이 향상된 비타민 C 약제학적 조성물 | |
WO2011126352A2 (ru) | Противотуберкулезный препарат на основе комплекса включения циклодекстрина с рифампицином и способ его получения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980134233.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09811535 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010527810 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12011500456 Country of ref document: PH Ref document number: MX/A/2011/002400 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 20117005172 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009811535 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0919194 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110302 |